Comparing aTyr Pharma (NASDAQ:ATYR) & CRISPR Therapeutics (NASDAQ:CRSP)

aTyr Pharma (NASDAQ:ATYR) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Volatility and Risk

aTyr Pharma has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500.

Earnings and Valuation

This table compares aTyr Pharma and CRISPR Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190,000.00	2,772.33	-$74.12 million	($0.62)	-8.66
CRISPR Therapeutics	$11.00 million	476.96	-$581.60 million	($4.76)	-11.40

aTyr Pharma has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 5.0% of aTyr Pharma shares are owned by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for aTyr Pharma and CRISPR Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1	0	1	1	2.67
CRISPR Therapeutics	1	7	9	2	2.63

CRISPR Therapeutics has a consensus target price of $65.75, indicating a potential upside of 21.18%. Given CRISPR Therapeutics’ higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than aTyr Pharma.

Profitability

This table compares aTyr Pharma and CRISPR Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Summary

CRISPR Therapeutics beats aTyr Pharma on 9 of the 14 factors compared between the two stocks.

About aTyr Pharma

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.